MARKET

CYAD

CYAD

Celyad Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.395
+0.035
+0.80%
Closed 16:00 09/17 EDT
OPEN
4.340
PREV CLOSE
4.360
HIGH
4.410
LOW
4.290
VOLUME
9.68K
TURNOVER
--
52 WEEK HIGH
10.31
52 WEEK LOW
3.760
MARKET CAP
68.10M
P/E (TTM)
-3.4936
1D
5D
1M
3M
1Y
5Y
Celyad Oncology Announces September 2021 Conferences Schedule
MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, ...
GlobeNewswire · 09/01 05:00
HC Wainwright & Co. Maintains Buy on Celyad Oncology, Lowers Price Target to $15
HC Wainwright & Co. analyst Edward White maintains Celyad Oncology (NASDAQ:CYAD) with a Buy and lowers the price target from $17 to $15.
Benzinga · 08/06 10:07
--HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating
MT Newswires · 08/06 09:17
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 08/05 12:04
Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial resul...
GlobeNewswire · 08/04 20:01
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
Benzinga · 08/01 14:13
Celyad Oncology to Announce First Half 2021 Financial Results and Host Conference Call
Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report first half 2021 fin...
GlobeNewswire · 07/29 05:00
Celyad Oncology highlights new CAR T product, gives data update
Celyad Oncology (CYAD) highlights new preclinical allogeneic armored CAR T candidate developed from its shRNA platform.The submission of IND application for CYAD-203, a new first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate,
Seekingalpha · 07/20 20:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYAD. Analyze the recent business situations of Celyad Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYAD stock price target is 17.37 with a high estimate of 19.85 and a low estimate of 14.89.
EPS
Institutional Holdings
Institutions: 13
Institutional Holdings: 283.94K
% Owned: 1.83%
Shares Outstanding: 15.49M
TypeInstitutionsShares
Increased
1
900
New
2
172.01K
Decreased
2
670.85K
Sold Out
1
87
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Co-Founder/Director
Michel Lussier
Chief Executive Officer/Executive Director/Executive Board
Christian Homsy
Chief Financial Officer/Executive Board/Primary Contact
Patrick Jeanmart
Chief Operating Officer
Gaetane Metz
Vice President
Richard Mountfield
Vice President - Research & Development/Executive Board
Peter De Waele
Vice President - Business Development
Georges Rawadi
Other
Seron Aymeric
Other
Philippe Dechamps
Other
Roland Gordon-Beresford
Non-Executive Director
Serge Goblet
Non-Executive Director
Hanspeter Spek
Non-Executive Director
William Wijns
Independent Director
Chris Buyse
Independent Director
Rudy Dekeyser
No Data
  • All
  • Financials
  • Insiders
No Data
About CYAD
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

Webull offers kinds of Celyad Oncology SA stock information, including NASDAQ:CYAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYAD stock methods without spending real money on the virtual paper trading platform.